These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 25917369)
61. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. Kornstein SG; Li D; Mao Y; Larsson S; Andersen HF; Papakostas GI CNS Spectr; 2009 Jun; 14(6):326-33. PubMed ID: 19668123 [TBL] [Abstract][Full Text] [Related]
62. Antidepressants for people with epilepsy and depression. Maguire MJ; Weston J; Singh J; Marson AG Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010682. PubMed ID: 25464360 [TBL] [Abstract][Full Text] [Related]
63. Resolution of sleepiness and fatigue: a comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union. Cooper JA; Tucker VL; Papakostas GI J Psychopharmacol; 2014 Feb; 28(2):118-24. PubMed ID: 24352716 [TBL] [Abstract][Full Text] [Related]
64. Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials. Jia Y; Zhu H; Leung SW BMJ Open; 2016 Jun; 6(6):e010142. PubMed ID: 27267106 [TBL] [Abstract][Full Text] [Related]
65. Escitalopram: a review of its use in the management of major depressive disorder in adults. Garnock-Jones KP; McCormack PL CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989 [TBL] [Abstract][Full Text] [Related]
66. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Lam RW; Lönn SL; Despiégel N Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664 [TBL] [Abstract][Full Text] [Related]
69. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Kasper S; Corruble E; Hale A; Lemoine P; Montgomery SA; Quera-Salva MA Int Clin Psychopharmacol; 2013 Jan; 28(1):12-9. PubMed ID: 23023074 [TBL] [Abstract][Full Text] [Related]
70. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial. Knorr UB Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724 [TBL] [Abstract][Full Text] [Related]
71. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066 [TBL] [Abstract][Full Text] [Related]
72. Duloxetine versus other anti-depressive agents for depression. Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926 [TBL] [Abstract][Full Text] [Related]
73. Fluoxetine versus other types of pharmacotherapy for depression. Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997 [TBL] [Abstract][Full Text] [Related]
74. Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Gonul AS; Akdeniz F; Donat O; Vahip S Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):889-91. PubMed ID: 12921926 [TBL] [Abstract][Full Text] [Related]
75. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Thase ME; Haight BR; Richard N; Rockett CB; Mitton M; Modell JG; VanMeter S; Harriett AE; Wang Y J Clin Psychiatry; 2005 Aug; 66(8):974-81. PubMed ID: 16086611 [TBL] [Abstract][Full Text] [Related]
76. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965 [TBL] [Abstract][Full Text] [Related]
77. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953 [TBL] [Abstract][Full Text] [Related]
79. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression. Zhang Y; Becker T; Ma Y; Koesters M BMC Psychiatry; 2014 Aug; 14():245. PubMed ID: 25159460 [TBL] [Abstract][Full Text] [Related]
80. [Fluoxetine: an update of its use in major depressive disorder in adults]. Gourion D; Perrin E; Quintin P Encephale; 2004; 30(4):392-9. PubMed ID: 15597466 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]